GLPwatch

Exendin-4 prevented pancreatic beta cells from apoptosis in (Type I) diabetic mouse via keap1-Nrf2 signaling.

Exp Biol Med (Maywood) · 2019

Last updated 2026-05-28

In a study on diabetic mice, the drug exendin-4 reduced cell death in pancreatic beta cells by activating a pathway called Keap1-Nrf2-ARE. When researchers blocked the Nrf2 protein, cell death increased, and the protective effect of exendin-4 was weakened.

AI summary of the abstract below.

JournalExp Biol Med (Maywood), 2019
Citations2
Relative citation ratio0.11
NIH percentile8
Molecules
Conditions studied Type 2 Diabetes

Abstract

Nrf2 is an essential part of the defense mechanism of vertebrates and protects them from surrounding stress via participation in stimulated expression of detoxification as well as antioxidant enzymes. It also exerts a role in defending hosts from different stress in the environment, including reactive oxygen species. Our study investigates the role of exendin-4 on Nrf2 pathway as well as cell death in pancreatic β-cell and in non-obese diabetic mice. Result of study indicates exendin-4 mediates activation of Keap1-Nrf2-ARE pathway and may serve as a potential agent to treat type I diabetes mellitus. In our research, we observed excessive reactive oxygen species production, low level of cell death, and PKC phosphorylation on exendine-4 treatment. Nrf2 knockdown led to suppression of reactive oxygen species generation as well as increasing apoptosis. Moreover, siRNA-mediated Nrf2 down-regulation attenuated the suppressive effect of exendin-4 in pancreatic β-cell viability, via modulating apoptosis promoting- and counteracting-proteins, Bax, and Bcl-2.

Verbatim abstract via PubMed 30638057 ↗